Numerous Types of Stem Cells Possess Potential to Treat Congenital Hydrocephalus
Journal Title: Journal of Regenerative Medicine & Biology Research - Year 2023, Vol 4, Issue 1
Abstract
Twenty-five percent of premature neonate’s experience Intraventricular Hemorrhage (IVH) and 10% of these events are complicated further by the occurrence of hydrocephalus. The number of infants at high risk for IVH and therefore Post Hemorrhagic Hydrocephalus (PHH), is rising due to improved survival rate of premature infants. Fetal onset hydrocephalus is a heterogeneous brain disorder involving Cerebrospinal Fluid (CSF) dynamics and is a result of both genetic and environmental factors. Mesenchymal stem cells present themselves as a potent therapeutic modality for brain injury based on their multipotency, anti-inflammatory, antioxidant and angiogenic functions. Numerous animal model clinical provide evidence that Mesenchymal Stem Cells (MSCs) can target nearly all mechanisms involved in the pathogenesis of hydrocephalus. Unrestricted somatic stem cells possess anti-inflammatory and immunomodulatory properties as well as release growth factors and cytokines with known neuroprotective and axonal growth promoting functions. Neural stem cells are self-sustaining, pluripotent cells that have the capability to correct brain maldevelopment, reduce brain damage, promote regeneration and repair via neurotrophic and immunomodulatory mechanisms and direct cell replacement. For these reasons, stem cells possess the potential to be an effective therapy and should be further researched.
Authors and Affiliations
Hetvi Solanki, Vincent S Gallicchio
Keywords
Related Articles
- EP ID EP715200
- DOI https://doi.org/10.46889/JRMBR.2023.4107
- Views 33
- Downloads 0
A Gout Flare Caused by the Administration of Platelet Rich Plasma: A Clinical Case
The therapy with Platelet Rich Plasma (PRP) administered in degenerated or injured musculoskeletal tissues is a new and promising regenerative treatment option. Traditionally, it is considered that as PRP represents an a...
Use of Stem Cells to Treat Left Ventricular Hypertrophy
Left Ventricular Hypertrophy is a multifactorial condition involving genetic and signaling pathways. Current recommendations for treating hypertensive LVH include ACE inhibitors, RAS and CCBs. Despite numerous drug thera...
The Jounced Entrails-Intestine in COVID-19
Coronavirus disease 2019 (COVID-19), initiated by contemporary coronavirus is a pandemic which engenders severe respiratory disease. SARS-CoV-2 preponderantly transmits through airborne particles and mammoth respirator...
The Future Role of Mesenchymal Stem Cells in Tissue Repair and Medical Therapeutics: Realities and Expectations
Mesenchymal Stem Cells (MSCs); which were first described by Alexander Fridenstein in the 1960s; are heterogeneous, non-hematopoietic, adult multipotent stromal progenitor cells that are capable of self-renewal and dif...
Celiac Disease and the Potential of Stems Cells as Treatment
Celiac disease is characterized by having a broad spectrum of clinical presentations ranging from asymptomatic cases to classical gastrointestinal manifestations of disease and cases of severe progression in refractory c...